Literature DB >> 7106157

Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites.

B Vandel, M Sandoz, S Vandel, G Allers, R Volmat.   

Abstract

The urinary excretion of amitriptyline (AMT) and seven of its metabolites was studied by mass spectrometry in 10 depressive in-patients treated to steady-state condition with oral amitriptyline. An average of 68.3% of the dose was recovered in the urine, of which 68.6% was present as conjugates. Hydroxynortriptyline and its conjugate represented 54% of the total recovery. There was marked variation in metabolite pattern between patients. The variations were not due to concomitant medication with benzodiazepines. There was no correlation between the plasma and urine concentrations of AMT and its metabolites, except for amitriptyline conjugates. Two groups of patients could be distinguished - low and high excretors, who displayed alternative routes of metabolism. The disappearance rate of AMT from plasma was determined by the metabolic clearance of AMT to its metabolites. It varied considerably between patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106157     DOI: 10.1007/BF00545222

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  44 in total

1.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

2.  Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

Authors:  L F Gram; K Overo; L Kirk
Journal:  Am J Psychiatry       Date:  1974-08       Impact factor: 18.112

3.  Studies of human urinary and biliary metabolites of nortriptyline with stable isotope labeling.

Authors:  D R Knapp; T E Gaffney; R E McMahon; G Kiplinger
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

4.  Binding and oxidation of amitriptyline and a series of its oxidized metabolites in liver microsomes from untreated and phenobarbital-treated rats.

Authors:  C von Bahr
Journal:  Xenobiotica       Date:  1972-05       Impact factor: 1.908

5.  Interactions of benzodiazepines with warfarin.

Authors:  M Orme; A Breckenridge; R V Brooks
Journal:  Br Med J       Date:  1972-09-09

6.  Pharmacokinetics and biological effects of nortriptyline in man.

Authors:  F Sjöqvist; B Alexanderson; M Asberg; L Bertilsson; O Borgå; B Hamberger; D Tuck
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

7.  Amitriptyline and its demethylation-rate.

Authors:  A Coppen; V A Rao
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

8.  Determination of amitriptyline and its major basic metabolites in human urine by high-performance liquid chromatography.

Authors:  S R Biggs; L F Chasseaud; D R Hawkins; I Midgley
Journal:  Drug Metab Dispos       Date:  1979 Jul-Aug       Impact factor: 3.922

9.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

10.  Benzodiazepines and tricyclic antidepressant plasma levels.

Authors:  G Silverman; R A Braithwaite
Journal:  Br Med J       Date:  1973-07-07
View more
  7 in total

1.  Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy.

Authors:  B Becher; W Fischer; Z Taneri; E Scholz; W E Müller; U Breyer-Pfaff
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man.

Authors:  A E Balant-Gorgia; P Schulz; P Dayer; L Balant; A Kubli; C Gertsch; G Garrone
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

3.  Variability of diphenhydramine N-glucuronidation in healthy subjects.

Authors:  D Fischer; U Breyer-Pfaff
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.441

4.  Biotransformation of amitriptyline in alcoholic depressive patients.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Metabolism of amitriptyline in patients with chronic renal failure.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; B Hory; Y St Hillier; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice.

Authors:  F Coudore; J Fialip; A Eschalier; J Lavarenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

7.  Urinary excretion of conjugates of dothiepin and northiaden (mono-N-demethyl-dothiepin) after an oral dose of dothiepin to humans.

Authors:  K Kawahara; T Awaji; K Uda; Y Sakai; Y Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jan-Mar       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.